Exosome RNA Exosome RNA Research & Industry News
Capricor Therapeutics, Inc. (NASDAQ:CAPR) belongs to Healthcare sector. Its weekly performance is -2.50%. On last trading day company shares ended up $4.68. Capricor Therapeutics, Inc. (NASDAQ:CAPR) distance from 50-day simple moving average (SMA50) is -22.39%. On 17 June, Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced the appointment of Houman Hemmati, M.D., Ph.D. to the newly created position of Vice President of Medical and Clinical Development for New Therapies. In this role, Dr. Hemmati will work to drive promising new therapies such as Capricor’s exosome platform into clinical development as he works closely with the R&D, manufacturing and product development teams.
Don't Miss
- Researchers discover neurogenesis-promoting effect of extracellular vesicles produced by brain stem cells
- UAB researcher receives $7 million R35 grant to study pathogenic exosomes in COPD
- UC Davis researchers to harness the cell’s messaging system
- Click chemistry extracellular vesicle/peptide/chemokine nanocarriers for treating central nervous system injuries
- Improved isolation of extracellular vesicles by removal of both free proteins and lipoproteins
- Plasma-derived small extracellular vesicles unleash the angiogenic potential in head and neck cancer patients
- Cancers in distant organs alter liver function
- DNA-driven photothermal amplification transducer for highly sensitive visual determination of extracellular vesicles
- New production process for therapeutic nanovesicles
- PhD position available – development of milk extracellular vesicles for therapeutic applications
